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Abstract
Background: Chronic recurrent multifocal osteomyelitis (CRMO) is a rare condition that commonly affects the
clavicle and pelvis.
Case presentation: We report here a case a 12 years old girl with CRMO arising with recurrent episodes of left
supraorbital headache, followed by the appearance of a periorbital dyschromia. Magnetic resonance imaging (MRI)
of the skull and orbits revealed an important subacute inflammatory process. Few months after, the child presented
a painful swelling of the left clavicle; the histological examination of the related biopsy allowed to establish the
diagnosis of CRMO.
Conclusion: CRMO presenting as acute headache involving neurocranium is rare; to our knowledge this is the first
recognized case in the world literature.
This pathological condition is frequently misdiagnosed as infection or neoplasm and needs a deep investigation for
the differential diagnosis. The physical, laboratoristic and instrumental diagnostic investigations of the patient and
the treatment employed are described in detail.
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Background
Chronic recurrent multifocal osteomyelitis (CRMO), also
known as chronic nonbacterial osteomyelitis, is a rare,
noninfectious inflammatory disorder that causes multi-
focal lytic bone lesions with swelling and pain [1]. The
course of the disease is characterized by periodic exacer-
bations and remissions, but long term outcome remains
unclear [1].
CRMO was first described in 1972 by Giedon et al.
[2]; since 1972 more than 260 cases have been reported
in the medical literature [3]. The prevalence of this con-
dition is estimated at 1-2/106 (Orphanet.net), but it
might be underrated [4]. CRMO primarily affects young
girls with a female: male ratio of 4:1 and the mean age
onset is 10 years [3, 5]; the mean time from the symp-
toms onset to the diagnosis is 18 months, ranging from
few weeks to few years [5].
CRMO may manifest only as multifocal bone lesions,
but it is frequently associated with other inflammatory
conditions, including peripheral arthritis, sacroileitis,
psoriasis, pustulosis palmaris et plantaris, pyoderma
gangrenosum [6, 7], inflammatory bowel disease (IBD)
[6], severe acne, Sweet syndrome [8], Wegener’s granulo-
matosis [9] and Takayasu’s arteritis [7]. Individual bone
lesions may be asymptomatic, but typically cause swell-
ing, warmth, and often a dramatic degree of pain that
interfere with physical function, psychosocial health, fi-
nally impairing the quality of life of the patient.
CRMO, widely believed to represent the pediatric
equivalent of Synovitis, Acne, Pustulosis, Hyperostosis,
Osteitis (SAPHO) syndrome, originally described in 1987
by Chamot et al. [10], is characterized by the association
of osteoarticular disorders and skin manifestations.
Initially CRMO was thought to share similarities with
the spondylarthropathies [11], based on the links be-
tween CRMO and SAPHO syndrome and on the pres-
ence in a substantial number of CRMO patients of
psoriasis or chronic inflammatory bowel disease (Crohn’s
disease or ulcerative colitis) [3, 4]. However, recent
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genetic data from mice with Chronic Multifocal Osteo-
myelitis (CMO) and humans with Majeed syndrome
(CRMO with dyserythropoietic anemia), suggest that
CRMO may belong to the vast family of autoinflamma-
tory diseases [4]. They assemble a group of different
conditions secondary to mutations of genes coding for
proteins that play a pivotal role in the regulation of the
inflammatory response. The discovery of the “inflamma-
some” allowed to define more than 30 autoinflammatory
disorders, most of which arising during childhood [12,
13]. These entities are characterized by the presence of
recurrent episodes of spontaneous inflammation and by
the absence of high titles of autoantibodies or autoreac-
tive T cells. The underlying mechanism of this condition
results from the involvement of the innate immune
response [12].
Case presentation
A 12-year-old girl, suffering from recurrent episodes of
left supraorbital headache since the age of 11 years, pre-
sented at Department of Pediatrics (Immunology and
Rheumatology’s ambulatory) of the University of Pisa.
The physiological anamnesis was apparently mute. Be-
cause of the persistence of symptoms, the child performed
a brain magnetic resonance imaging (MRI) which resulted
negative.
After consultation with a neuropsychiatric she started
a therapy with sertraline. A month later, she presented
an hyperemic periorbital circle around the left eye
(Fig. 1). Due to persistence of these symptoms, a MRI of
the skull and orbits was performed, which revealed an
important subacute inflammatory process of the bone
structures such as squama of the frontal bone, orbital
process of the zygomatic bone and of the greater wing of
the sphenoid bone (Fig. 2).
After few months the child developed a painful swell-
ing of the sternal end of the left clavicle, covered with
normal skin (Fig. 3).
Laboratory results showed a modest increase of in-
flammation parameters (ESR 49 mm/h, CRP 3.88 mg/
dL) with normal complete blood count, liver and renal
function. The abdominal ultrasound and the chest X-ray
were normal. A whole-body scintigraphy with 99Tc
revealed the presence of “foci” of pathological high-
uptake (left frontal supraorbital area with extension to
ethmoid bone and sternal end of the left clavicle), with-
out other pathological areas in the remaining skeletal
segments. X-ray of the left clavicle confirmed the pres-
ence of an area of osteolysis. Computerized Tomography
Scan (CT) (Figs. 4, 5) revealed a rearrangement and
thickening of the orbital spongy part of the left frontal
bone and an infiltration of pathological tissue extended
to the adjacent frontal squama, causing areas of osteoly-
sis: these images were suggestive of an inflammation-
infectious process.
A biopsy of the osteolytic lesion of the left clavicle was
performed: all cultures were negative; the related histo-
pathology showed a bone with marked signs of wide-
spread osteoblastic/osteoclastic remodeling (Fig. 6), with
inter-trabeculae areas of myofibroblasts. Bone was infil-
trated by a granulomatous tissue rich of lymphocytes,
neutrophils, giant cells with osteoblatic shape and histio-
cytes with hematic pigment inside, displaying CD68 anti-
gen to the immunohistochemistry analysis. A fine vascular
reticulum CD31+ and CD34+ in the absence of cyto-
keratin positive elements was observed. No neoplastic
cells were identified or cells suggesting histiocytosis of
Langherans cell type. This histopathological pattern
strongly suggested an inflammatory reparative process;
the immunohistochemistry staining (pS-100, CD1a, actin/
1A4, CD68/KP-1, Ki-67/MB-1) definitively excluded the
presence of neoplastic tissue. Clinical history, physical
signs, instrumental investigations and histopathological
pattern were highly suggestive of CRMO. After starting
anti-inflammatory therapy with naproxen, the child car-
ried out a clinical, biological and instrumental (MRI total
body with STIR sequences) follow-up every 6 months.
After 4 months from diagnosis the clinical picture was
negative and a MRI showed the improvement of previous
findings; therefore the therapy with naproxen was discon-
tinued. In the following 12 months the child again experi-
enced recurrent attacks of headache associated with bone
painful mainly localized to upper extremities. Although
MRI STIR sequences total body were negative, the ob-
served picture of “bone remodeling” of the cranial region,
in absence of enhanced inflammatory markers, led us to
plan therapy with bisphosphonates.
Conclusion
Chronic recurrent multifocal osteomyelitis (CRMO) is a
rare, noninfectious inflammatory recurrent disorder, with
periodic exacerbations and remissions, but long term out-
come remains unclear [1].
The diagnosis is of exclusion and it is based on the
clinical and radiological data. In most cases biopsy and
bone histology are mandatory to confirm the diagnosis.
Fig. 1 Marked hyperemia with periorbital edema of the left upper
and lower eyelids
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CRMO may manifest as isolated multifocal bone lesions,
but is frequently associated with other inflammatory con-
ditions [6–9].
The peculiarity of our case concerns especially the ini-
tial site of disease, in the orbital region, causing recur-
rent headache attacks.
Therefore, the primary unusual location caused difficul-
ties in the differential diagnosis with other pathological
conditions such as: Langerhans cell histiocytosis, osteo-
blastoma, osteosarcoma.
The appearance of a second location of the disease at
the level of the medial portion of left clavicle (considered
as “typical site” in 5 % of cases reported in literature
[14]), and the complexity of the investigations above de-
scribed, allowed the diagnosis of CRMO.
Our patient presents some similarities with a previ-
ously described case of CRMO arising with recurrent
painful swelling of cheeks [15]. In both cases a cranial
involvement is reported, but with different osseous sites
(the mandibular ramus in the previous one and frontal,
orbital and sphenoid bones in our case), associated with
slightly elevated inflammation parameters. Therefore the
peculiarity of our case is the initial site of the disease in
the neurocranium (the first case described), causing mis-
leading headache attacks.
Fig. 2 MRI: subacute inflammatory process at the level of the left orbital region with involvement of periorbital soft tissue and the bone structures
Fig. 3 Painful swelling covered by normal skin of the sternal end of
the left clavicle Fig. 4 CT scan three-dimensional reconstruction
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CRMO has been recently considered an inflammatory
disease, as evidenced by genetic data derived from
experimental murine model and from humans affected
by Majeed Syndrome, showing the mutations of genes
involved in the regulation of inflammatory response
(PSTPIP2 and LPIN2 respectively localized on chromo-
some 18p) [16].
Interestingly, the observed low mannose-binding lectin
(MBL) production in some CRMO patients, presenting
with MBL genetic variants, suggested a linkage of
CRMO with the involvement of the innate immunity
[17]. The MBL is a serum protein that plays a role in the
innate immune response; it binds to carbohydrates on
the surface of a wide range of pathogens, where it
activates the complement system or directly acts as op-
sonin, by enhancing phagocytosis, through the binding
to cell surface receptor expressed on phagocytic cells
[17]. Polymorphism in the first exon of the MBL2 gene
is known to lead to a diminished production of MBL, as
well as an impairment of its function. Recent studies
suggested that the variations in MBL serum concentra-
tion are associated with increased risk of infectious and
autoimmune diseases [17]. In our patient, MBL2 genetic
screening was performed by polymerase chain reaction
amplification from genomic DNA and subsequent direct
sequencing of the amplicons. The analysis was per-
formed on six functional nucleotide variations, (three in
the promoter region (−550, −221,+4) and in the exon 1
(position 52,54,57) of the gene, that are in linkage dis-
equilibrium and whose haplotypes are associated with
different quantitative production of MBL. The combined
genotype, in our patient, was LYQA/LYQA, associated
with a normal protein production.
CRMO has been long believed to have a benign
self-limited course and to resolve without leaving any
consequential residual damages, but recent data sug-
gest that physical impairments may persist in up to
50 % of patients [3]. They consist in chronic pain and
bone deformities, impairing physical and emotional
health [3, 5].
The treatment of CRMO has been widely empiric; al-
though NSAIDs remain the first choice, the alternative
therapy is represented by bisphosphonates and biologic
drugs such as TNF antagonists (etanercept) or inhibitors of
IL-1 (anakinra), but further studies are needed to evaluate
the safety of long-term of these drugs in children. Further-
more, a multidisciplinary approach involving different spe-
cialties (pediatrics, rheumatology, radiology, orthopedics,
pathology and in selected cases also physiotherapy, plastic
surgery, gastroenterology and dermatology) is necessary.
The child was initially treated with a first-line drug,
belonging to the class of anti-inflammatory drugs, which
resulted to a progressive resolution of the lesions in few
months.
However, the recurrence of bone pain episodes, ob-
served during the follow-up of patient, although not as-
sociated with perceptible alterations at the instrumental
exams (MRI STIR sequences), led us to introduce a sec-
ond line drug, in attempt to reduce the progression of
the disease. The therapeutic choice turned towards the
class of bisphosphonates, according to the most recent
indications of the literature [16]. Their anti-osteoclastic
activity has been clearly established by the described
morphological and functional cellular alterations, typical
of the active phase of bone resorption such as the loss of
the brush border and of the cytoplasmic vacuoles [18];
the reduction of the lactic acid production, the proton
accumulation, the synthesis of enzymes lysosomes and
Fig. 5 CT: remodeling and bone erosion. Note the thickness of the
soft tissues (edema, inflammation)
Fig. 6 Bone with marked signs of widespread
osteoblastic/osteoclastic remodeling
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prostaglandins, of the acid phosphatase and pyropho-
sphatase, fundamental to the phagocytic activity of oste-
oclasts has also been reported [18].
Therefore the variety of the molecular targets of
bisphosphonates indicate them as a relevant therapeutic
approach of cases of CRMO, characterized by the pre-
dominance of the bone involvement on the systemic in-
flammation [4], in order to prevent the bone damage
and the severe impairment of quality of life.
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